Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Terns Pharmaceuticals, Inc. | tern-ex322_8.htm |
| EX-32.1 - EX-32.1 - Terns Pharmaceuticals, Inc. | tern-ex321_6.htm |
| EX-31.2 - EX-31.2 - Terns Pharmaceuticals, Inc. | tern-ex312_7.htm |
| EX-31.1 - EX-31.1 - Terns Pharmaceuticals, Inc. | tern-ex311_9.htm |
| EX-4.3 - EX-4.3 - Terns Pharmaceuticals, Inc. | tern-ex43_284.htm |
| 10-K - 10-K - Terns Pharmaceuticals, Inc. | tern-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No 333-253085) of Terns Pharmaceuticals, Inc. of our report dated March 30, 2021, with respect to the consolidated financial statements of Terns Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Terns Pharmaceuticals for the year ended December 31, 2020.
/s/ Ernst & Young LLP
San Jose, California
March 30, 2021